Document Detail


Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon.
MedLine Citation:
PMID:  23266234     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The treatment of resistant hypertension has undergone remarkable advancements in recent years. Endovascular radio frequency renal sympathetic denervation (RSD) has shown initial success in treating resistant hypertension by targeting the connection between the brain and renal sympathetic nerves. However, the encouraging results of first-generation RSD have been tempered by important procedural limitations and a need for long-term results of safety and efficacy. In an effort to build on early clinical success, several second-generation RSD technologies are now being developed that may improve procedural safety and efficacy. Preliminary evidence for some of the latest technologies is now available. In this review, we summarize the current evidence in support of RSD and consider unique features of several new technologies that are likely to refine the endovascular treatment of resistant hypertension.
Authors:
Matthew C Bunte; Eduardo Infante de Oliveira; Mehdi H Shishehbor
Related Documents :
2376174 - A new method for measurement of airway occlusion pressure.
24145974 - Assessment of a new type i endoleak repair technique using an anchoring device.
12137664 - Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pul...
8539354 - Barotrauma.
1893644 - Control of blood pressure by the renin-angiotensin-aldosterone system.
20233364 - Basic aspects of phase changes under high pressure.
Publication Detail:
Type:  Journal Article; Review     Date:  2012-12-19
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  6     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-25     Completed Date:  2013-07-09     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects*
Catheter Ablation
Catheters
Drug Resistance*
Endovascular Procedures* / adverse effects,  instrumentation
Equipment Design
Humans
Hypertension / diagnosis,  drug therapy,  physiopathology,  surgery,  therapy*
Kidney / innervation*
Sympathectomy / adverse effects,  instrumentation,  methods*
Treatment Failure
Ultrasonic Therapy
Chemical
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing per...
Next Document:  Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscula...